EUVIMEDEUVIMED entdecken
CrossrefInfokarte

In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line

Paul Curley, Marco Giardiello, Neill J. Liptrott, David Dickens, Darren M. Moss, James J. Hobson, Alison C. Savage, Tom O. McDonald, Marco Siccardi, Steve Rannard, Andrew Owen

Journal of Interdisciplinary Nanomedicine · 2017

DOI: 10.1002/jin2.32 ↗
AbstractBibliografische Angaben

Abstract

Abstract The antiretroviral drug efavirenz displays many desirable pharmacokinetic properties such as a long half‐life enabling once daily dosing but suffers from central nervous system safety issues. Various nanotechnologies have been explored to mitigate some of the limitations with efavirenz. While there has been progress in increasing the bioavailability, there has been no attempt to assess the impact of increased exposure to efavirenz on central nervous system safety. The uptake of aqueous and solid drug nanoparticle (SDN) formulations of efavirenz was assessed in the human cerebral microvessel endothelial cells/D3 brain endothelial cell line. The mechanisms of uptake were probed using a panel of transport and endocytosis inhibitors. The cellular accumulation of an efavirenz aqueous solution was significantly reduced by amantadine, but this was not observed with SDNs. The uptake of efavirenz SDNs was reduced by dynasore, but concentrations of the efavirenz aqueous solution were not affected. These data indicate that efavirenz is a substrate for transporters in brain endothelial cells (amantadine is an inhibitor of organic cation transporters 1 and 2), and formation of SDNs may bypass this interaction in favour of a mechanism involving dynamin‐mediated endocytosis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →